POSlTRANSPLANT Iymphoproliferative disease (PTLD) is a well-recognized complication of immunosuppression. I Previous reports of patients immunosuppressed with cyclosporine (eyA) revealed a 1.7% incidence of PTLD in solid-organ transplant recipients and a strong association with the Epstein-Barr virus «EBV). ~ The use of FK 506 in clinical trials has resulted in improved patient and graft surviv...

T psyc,hiatric care of patients with organ transplants IS a rapidly groWIng area. Morbidity and mortality of transplantation are directly related to a number of factors including organ rejection and adverse complications of ~edications. FK 506, a promising new immunosuppressive drug, appears to significantly reduce the rate of rejection. During our center's several years of experience using FK ...

We have recently isolated an abundant cytosolic protein from human T-cells which specifically binds the immunosuppressive agent, FK-506. The FK-506-binding protein (FKBP) is a member of a novel class of proteins possessing peptidyl-prolyl cis-trans isomerase activity. These proteins are believed to play an important role in accelerating the rate at which proteins fold into their native conforma...

The immuno-pharmacological profile of a novel immunosuppressive agent, FK-506 produced by a streptomycete, is presented here. We proceeded to test the effect of the agent on various in vitro immune systems. It showed that mixed lymphocyte reaction, cytotoxic T cell generation, the production of T cell-derived soluble mediators such as interleukin 2 (IL-2), interleukin 3 and gamma-interferon and...

FK 506 (Tanolimus. Prograf'") has been recently approved by the Food and Drug Administration (FDA) for baseline immunosuppression following orthotopic liver transplantation (OLT). The drug was first used clinically in 1989. 1 and I year later at the Thirteenth International Congress of Transplantation Society. San Francisco. CA 1990. extensive reports were given from our center describing the p...

conclusions the analysis of the pro-apoptotic gene to anti-apoptotic gene expression ratio (bad /bcl-xl) confirmed that expression of the pro-apoptotic gene significantly decreased (p value ˂ 0.001) under the ischemia/reperfusion condition. in contrast, the expression of the anti-apoptotic gene increased after administration of fk-506 (p value ˂ 0.001). results the quantitative results of real-...

Five repeated topical applications of 2,4-dinitrofluorobenzene to the ears of BALB/c mice resulted in contact dermatitis on the ears as well as significant elevation in dinitrophenol-specific IgE antibody and total IgE in the serum. FK-506 and cyclosporin A inhibited the development of contact dermatitis in terms of skin thickness and histopathological changes of skin lesions. On the contrary, ...

The experimental immunosuppressive drug FK 506 was given to 36 renal transplant recipients, many of whom were highly sensitized. Ten were undergoing kidney retransplantation, 10 also underwent liver transplantation at an earlier time (6 patients) or concomitantly (4 patients), and 2 patients received a third organ (heart or pancreas) in addition to a liver and kidney. With follow-ups of 4 to 13...

Rapamycin and FK-506 are immunosuppressive drugs that bind a ubiquitous immunophilin, FKBP12, but immunosuppressive mechanisms and side effects appear to be different. Rapamycin binds renal FKBP12 to change renal transport. We used cell-attached patch clamp to examine rapamycin's effect on Na(+) channels in A6 cells. Channel NP(o) was 0.5 +/- 0.08 (n = 6) during the first 5 min but fell close t...